62 results
8-K
EX-1.1
CGTX
Cognition Therapeutics Inc
13 Mar 24
Entry into a Material Definitive Agreement
4:07pm
, including those relating to transactions with affiliates, environmental, safety or similar laws, federal or state laws relating to discrimination
8-K
EX-99.1
CGTX
Cognition Therapeutics Inc
4 Jan 24
Other Events
4:21pm
Period (24 mo) Safety (4 wk) Assessments ‐ Age: ≥ 50 ‐ Diagnosis of dry AMD ‐ BCVA ≥ 24 letters (ETDRS) ‐ GA lesion ≥ 2.5 and ≤17.5mm2 ‐ Change in GA … lesion area (FAF) ‐ Ellipsoid zone area (SD-OCT) ‐ Drusen volume (SD-OCT) ‐ Safety Randomized 1:1 Placebo (n=123) CT1812 (n=123) Oral QD Administration
8-K
EX-99.1
qji5up4b9x9c ly
12 Sep 23
Other Events
7:00am
8-K
EX-99.1
cod wim4kfi
28 Jun 23
Cognition Therapeutics Announces Positive Topline Results for CT1812 Phase 2 SEQUEL Study for Mild-to-Moderate Alzheimer’s Disease
7:27am
8-K
EX-99.2
d8mn53kesdk
28 Jun 23
Cognition Therapeutics Announces Positive Topline Results for CT1812 Phase 2 SEQUEL Study for Mild-to-Moderate Alzheimer’s Disease
7:27am
8-K
j1e1 x72ji21map4ax1
28 Jun 23
Cognition Therapeutics Announces Positive Topline Results for CT1812 Phase 2 SEQUEL Study for Mild-to-Moderate Alzheimer’s Disease
7:27am
8-K
EX-99.1
ly3gwf0al3oyihu ppi8
19 Apr 23
Developing disease-modifying medicines for degenerative disorders Analyst Breakfast April 2023
7:30am
8-K
EX-10.1
mxtarx9gz4dl7c4tf4
23 Dec 22
Entry into a Material Definitive Agreement
4:24pm
S-3
EX-1.2
7o0xi20ce fu
23 Dec 22
Shelf registration
4:16pm
8-K
EX-99.1
op0nq
16 Nov 22
Developing disease - modifying medicines for degenerative disorders November 2022
5:18pm
8-K
EX-1.1
93quyyv
14 Nov 22
Cognition Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
8:00am
424B4
14q4 062osfri
14 Nov 22
Prospectus supplement with pricing info
6:02am